Compare Mesoblast Limited (MESO) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Veritone Inc — how do they compare? Mesoblast Limited trades at $14.06 (market cap $1.75B), while Veritone Inc trades at $0.61 (market cap $59.46M). The key difference: Mesoblast Limited is far larger — about 29.4× Veritone Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Veritone Inc for 12 Days on average.
| MESO | VERI | |
|---|---|---|
Market Cap | $1.75B | $59.46M |
Volume | 239,027 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $20.96 | $8.39 |
52-Week Low | $13.19 | $0.59 |
Typical Hold Time | 14 Days | 12 Days |
Enterprise Value | $1.83B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Veritone (VERI) trades at $0.69, down 7.38% over 24 hours, reflecting ongoing investor concerns. The stock is technically bearish with negative earnings trends, including a net income margin of -117.54% for 2025. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, though these are overshadowed by a securities class action investigation and consistent quarterly losses.
The outlook remains challenging due to persistent unprofitability and high cash burn. The consensus price target of $3.75 offers significant upside if the company can achieve cost reductions and revenue growth, but execution risks and legal overhangs present substantial headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
